Protocol No.: S2206

Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
Principal Investigator
Safi, Danish
Phase
III
Age Group
Adult
Applicable Disease Site
Breast Cancer
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Kaitlyn Hager
Research Nurse

View on ClinicalTrials.gov